Saranas Named Finalist for Prestigious International Cardiovascular Innovation Award
HOUSTON–(BUSINESS WIRE)–Saranas, a medical device company with a new technology for real-time detection and monitoring of internal bleeding during endovascular procedures, today announced the company was named as one of the Top 4 Innovators at the International Conference for Innovations in Cardiovascular Systems (ICI) in Tel Aviv, Israel.
The ICI Innovation Award is one of the most significant and prestigious awards for medical intervention startups worldwide. The competition is a central element of the ICI conference, which attracts more than 1,800 attendees, including scientists, entrepreneurs, investors, medical device and pharmaceutical executives, and medical professionals specializing in cardiovascular interventions.
“We are very pleased and humbled to be recognized by this international conference as one of the four top cardiovascular innovators,” Saranas President and CEO Zaffer Syed said. “It is further validation that our Early Bird™ Bleed Monitoring System can have an important impact on healthcare costs and reduce the risk of death in patients undergoing endovascular procedures. This recognition from ICI provides substantiation that our innovative technology is disruptive and important for patients.”
The Early Bird includes a vascular access sheath with embedded sensors that are designed to detect and monitor bleeding from a blood vessel accidentally injured during endovascular procedures, such as a transcatheter aortic valve replacement, large bore hemodynamic support device placement, or other complex cardiac interventions, where the femoral artery or vein is used to gain vascular access to the heart. The technology was invented at the Texas Heart Institute.
Saranas Chief Medical Officer Dr. Philippe Genereux observed, “Our Early Bird system is designed to protect and in some cases, save the lives of patients undergoing an endovascular procedure by letting doctors detect the onset of bleeding early and take appropriate steps to address the bleed and allow the procedure to continue.”
Each year, more than 20 million people in the U.S. undergo vascular access procedures. About 5%, or 1 million of them, will experience severe procedural bleeding complications, resulting in significant additional healthcare expenditures and placing the patients at an increased risk of death. These “blind” bleeds are typically unnoticed until meaningful symptoms are present, by which time their management is much more challenging and can compromise patient outcomes. By being able to detect the onset of bleeding early, the Saranas Early Bird Bleed Monitoring System allows physicians to appropriately address the bleed and to continue the procedure.
About Saranas
Saranas is a privately held Houston, Texas-based medical device company focused on improving patient outcomes through early detection of internal bleeding complications. The company’s patented introducer sheath technology for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeding complications immediately, improving patient outcomes and lowering healthcare costs. For more information please visit: http://www.saranas.com/
Contacts
Opus Biotech Communications
Charles Craig, 404-245-0591
[email protected]
or
Dan Eramian, 425-306-8716
[email protected]